PARABILIS MEDICINES, INC. COMMON STOCK
NASDAQ: PBLS (Parabilis Medicines, Inc.)
最近更新时间: 6小时之前27.44
-0.18 (-0.67%)
新闻情绪
AIStockmoo 评分
| 价值 43% | 0.0 |
| 负债低。短期流动性充足。现金流为负。 参考 | |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 资本回报 参考 | NA |
| 盈利趋势 参考 | NA |
| 持仓估值 参考 | NA |
| 风险溢价 参考 | NA |
| 市场估值 参考 | NA |
| 时机 | NA |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| 趋势强度 参考 | NA |
| 技术形态 参考 | NA |
| K线形态 参考 | NA |
| 市场情绪 29% | 0.7 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 近期新闻大多正面。 参考 | |
| 持仓情绪 参考 | NA |
| 聪明钱 29% | 1.9 |
| 机构在最新13F申报中净+21.81%的股份:86家增持,20家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化+100.3%,回补天数8.3天(FINRA)。 参考 | |
| 内部交易活动 参考 | NA |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向一致,评分因此加强。 | |
| 不计入评分 | |
| 低于中期趋势线。 参考 | |
| 股价低于其52周平均水平。5年来下跌。 参考 | |
| 短期动能减弱。 参考 | |
| 股价接近支撑位。 参考 | |
| 最终评分 | 0.77 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Parabilis Medicines, Inc. | - | - |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B | 评分 |
|---|---|---|---|---|---|
| PBLS | 3 B | - | - | 3.38 | 0.8 |
| LEGN | 3 B | - | - | 2.59 | -1.6 |
| PVLA | 2 B | - | - | 10.82 | 0.9 |
| MAZE | 2 B | - | - | 4.13 | 0.9 |
| IMCR | 1 B | - | - | 3.24 | -0.2 |
| GPCR | 1 B | - | - | 1.01 | -0.8 |
|
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 6.93% |
| 机构持股比例 | 89.48% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Venbio Partners Llc | 30 Sep 2026 | 5,266,697 |
| Regeneron Pharmaceuticals, Inc. | 30 Sep 2026 | 4,166,666 |
该时间范围内无数据。
机构
机构持股比例: 90.89%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 86 | 16,079,357 |
| 减持 | 20 | 344,014 |
| 新建仓 | 60 | 11,492,551 |
| 清仓 | 10 | 178,319 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 11,052,337 | 8.3 |
| 15 Oct 2026 | 9,250,099 | 9.5 |
| 30 Sep 2026 | 8,261,483 | 4.8 |
| 15 Sep 2026 | 6,092,212 | 13.3 |
| 31 Aug 2026 | 5,517,704 | 14.2 |
| 14 Aug 2026 | 5,257,000 | 15.7 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 17 Nov 2026 | Yahoo Finance |
Does Parabilis Medicines (PBLS) Have the Potential to Rally 44.11% as Wall Street Analysts Expect?
The mean of analysts' price targets for Parabilis Medicines (PBLS) points to a 44.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
| 12 Nov 2026 | Yahoo Finance |
Parabilis Medicines: Q3 Earnings Snapshot
(AP) — Parabilis Medicines Inc. (PBLS) on Thursday reported a loss of $44… |
| 12 Nov 2026 | Yahoo Finance |
Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates
Presented updated Phase 1/2 data at ESMO Congress 2026 demonstrating a 72.2% objective response rate at the 32-week landmark and a favorable safety and tolerability profile for zolucatetide in desmoid tumors Reached alignment with the U.S. FDA on dose, regimen and trial design for upcoming PEDESTAL… |
| 03 Nov 2026 | Yahoo Finance |
Parabilis Medicines to Participate in Upcoming November Investor Conferences
CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced that Mathai Mammen… |
| 24 Oct 2026 | Yahoo Finance |
Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027
Parabilis Medicines (NASDAQ:PBLS) presented updated interim phase I/II data for investigational beta-catenin/TCF inhibitor zolucatetide in desmoid tumors at the European Society for Medical Oncology Congress in Madrid, reporting tumor responses, disease control and an FDA-aligned plan for a registra… |
| 24 Oct 2026 | Yahoo Finance |
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week landmarkDisease control rate of 100% across all response-evaluable patients receiving a starting dose of ≥450 mg, with no disease progression and no treatment discontinuations due to… |
| 20 Oct 2026 | Yahoo Finance |
Parabilis Medicines (PBLS) Stock May Trade At A Premium Despite Fresh Zolucatetide Trial Updates
Parabilis Medicines shares have retreated sharply in recent weeks, and that pullback puts fresh focus on what the current price implies relative to the drug developer’s book value. With sentiment swinging around new clinical updates, the key issue is how much of the balance sheet and pipeline risk… |
| 20 Oct 2026 | Yahoo Finance |
Parabilis Medicines (PBLS) Could Be 39% Undervalued As Zolucatetide Trial Expands
Parabilis Medicines (PBLS) has drawn fresh attention after announcing a new dose ranging cohort for its lead drug candidate, zolucatetide, in familial adenomatous polyposis, expanding an ongoing Phase 1/2 trial. The fresh zolucatetide cohort lands in a volatile stretch for Parabilis Medicines, with… |
| 20 Oct 2026 | Yahoo Finance |
What Does Parabilis Medicines (PBLS) Expanding Zolucatetide Into FAP Mean?
Parabilis Medicines (NasdaqGS:PBLS) reported updated Phase 1/2 clinical data for lead candidate zolucatetide in patients with desmoid tumors. The biotechnology company plans to present the new zolucatetide desmoid tumor data at a major oncology congress in 2026. Management has expanded zolucatetide… |
| 19 Oct 2026 | Yahoo Finance |
Parabilis Soars 13% on Upcoming ESMO Data for “First-in-Class” Desmoid Tumor Drug
Key TakeawaysParabilis Medicines shares rose 13% today after the company said it will present updated zolucatetide data in desmoid tumors at ESMO on Saturday, Oct. 24… |
| 19 Oct 2026 | Yahoo Finance |
Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026
Oral presentation will include updated data from the ongoing Phase 1/2 trial, with dose optimization arm designed to inform dose and regimen selection for Phase 3 registrational trial in desmoid tumors Company to host webcast on Saturday, October 24, 2026, at 6 p.m. CEST / 12 p.m. EDT CAMBRIDGE… |
| 14 Oct 2026 | Yahoo Finance |
Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors Zolucatetide directly inhibits β-catenin:TCF, targeting the APC-mutation biology that drives precancerous adenomatous polyp formation in… |
| 13 Oct 2026 | Yahoo Finance |
Phanes Therapeutics to participate in Longwood Healthcare Leaders Boston CEO, November 2-3, 2026
Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), announced that Ming Wang (CEO) will participate in Boston CEO, November 2-3, 2026, at the Mandarin Oriental Hotel in Boston, MA. He will speak on a… |
| 28 Sep 2026 | Yahoo Finance |
Sixty Degree Capital Extends Its Track Record as Five Portfolio Companies Enter the Public Markets in 2026
Sixty Degree Capital ("SDC"), a global, multi-stage venture capital firm investing across technology and healthcare, continued its strong portfolio momentum in 2026. Building on the firm's history of successful exits, five SDC portfolio companies have completed initial public offerings in 2026… |
| 23 Sep 2026 | Yahoo Finance |
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Directors. Mr. Sebulsky is a veteran healthcare portfolio manager and… |
| 01 Sep 2026 | Yahoo Finance |
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced its Chairman, President… |
| 25 Aug 2026 | Yahoo Finance |
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the appointment of Craig… |
| 24 Aug 2026 | Yahoo Finance |
Young startups miss out on biotech venture funding rebound, MassBio says
A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in opposite directions, as funding slows for young companies with the “riskiest science.” |
| 显示更多 | ||
投资组合